论文部分内容阅读
1972年 Babb 等在研究透析疗法的基础上,提出尿毒症患者某些症状与体液内中分子质(MMS)积聚有关,继而提出 MMS 与尿毒症症状关系的假说。MMS 是指存在于体液内分子量在300(或500)～115000dalton(1dalton=0.9921u)的各种物质的混合物(非均一成份)。体内 MMS 的来源迄今尚不十分清楚,一般认为毒尿症患者细胞代谢紊乱和排泄阻滞所引起的代谢产物积聚是 MMS 在体液内增
On the basis of the research of dialysis therapy in 1972, Babb et al. Proposed that some symptoms of patients with uremia are related to the accumulation of medium molecular weight (MMS) in body fluids, and then put forward the hypothesis that the relationship between MMS and uremia symptoms. MMS refers to a mixture (heterogeneous) of various substances present in bodily fluids with a molecular weight of 300 (or 500) to 115000 dalton (1 dalton = 0.9921 u). The origin of MMS in vivo so far is not yet fully understood, it is generally believed that metabolic disorders caused by metabolic disorders and excretion of patients with toxic urine accumulation of metabolites is MMS in vivo increase